• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, February 28, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Immune therapy for advanced bladder cancer yields promising results

Bioengineer by Bioengineer
June 8, 2014
in Immunology
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology in Chicago.

Immune therapy for advanced bladder cancer yields promising results

Daniel P. Petrylak, MD

The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The patients in the study were treated with MPDL3280A, a drug being developed by Genentech, a member of the Roche group.

At six weeks, the objective response rate (ORR) was 43%; at 12 weeks, the ORR was 52% in patients with PD-L1-positive tumors. A complete response — one showing no evidence of tumors — was seen in 7% of PD-L1 patients. In patients with PD-L1-negative tumors, the response rate was 11%.

The results in advanced bladder cancer patients “point to a new era in cancer treatment for a disease that has not seen a major advancement since the introduction of cisplatin-based combination therapy in the 1980s,” said the study’s senior author Daniel P. Petrylak, M.D., professor of medicine and urology at Yale Cancer Center and Yale School of Medicine. “We look forward to opening the phase II trial at Yale in June to confirm these findings.”

Yale Cancer Center enrolled 12 of the 68 patients on the trial at Smilow Cancer Hospital at Yale-New Haven.

Story Source:

The above story is based on materials provided by Yale Cancer Center.

Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Research reveals how bacteria defeat drugs that fight cystic fibrosis

February 26, 2021
IMAGE

Lethal house lures reduce incidence of malaria in children

February 26, 2021

Openly available toolkit to help lab-based coronavirus research

February 25, 2021

NIH awards UC San Diego $33 million for five COVID-19 diagnostic projects

February 25, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    638 shares
    Share 255 Tweet 160
  • People living with HIV face premature heart disease and barriers to care

    82 shares
    Share 33 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    38 shares
    Share 15 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Technology/Engineering/Computer ScienceMedicine/HealthcancerInfectious/Emerging DiseasesEcology/EnvironmentMaterialsCell BiologyClimate ChangeBiologyGeneticsPublic HealthChemistry/Physics/Materials Sciences

Recent Posts

  • Predicts the onset of Alzheimer’s Disease (AD) using deep learning-based Splice-AI
  • When foams collapse (and when they don’t)
  • UTA researcher explores effects of trauma at the cellular, tissue levels of the brain
  • Picture books can boost physical activity for youth with autism
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In